NPS Moves Toward Status As Global Orphan Drug Firm With Takeda Agreement
This article was originally published in The Pink Sheet Daily
In a deal that moves a $50 million equity stake to Takeda, NPS reacquires ex-U.S. rights to teduglutide and PTH 1-84, enabling the New Jersey firm to position itself as a worldwide orphan drug specialist. Takeda also can earn a $30 million one-time, sales-dependent milestone under the deal.
You may also be interested in...
Endocrinoloigc and Metabolic Drugs Advisory Committee will weigh in on Natpara for hypoparathryodism Sept. 12.